We examined the immunohistochemical expression of VASH1 and CD34 at both of the intratumoral and normal areas to elucidate the biological significance of VASH1 in clinically low-risk PCa (Figures 1, 2). This evidence concerns the gene VASH1 and posterior cortical atrophy.